Form 4: Vaccinex Director Chrystyna Bedrij-Stecyk Reports Stock Option Grant

Director Chrystyna Bedrij-Stecyk reports the acquisition of 10,108 stock options in Vaccinex, Inc.

Summary

• Chrystyna Bedrij-Stecyk, a director of Vaccinex, Inc., filed a Form 4 with the SEC.
• The report details the acquisition of 10,108 stock options on May 10, 2024, at an exercise price of $5.75.
• These options were granted pursuant to the Company's 2018 Omnibus Incentive Plan and expire on May 10, 2034, or five years following retirement or cessation of services, whichever occurs first.
• The filing also reflects the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.
• The reporting person also holds other stock options with various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. The reverse stock splits indicate potential past difficulties in maintaining share price.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The long expiration date of the options (May 10, 2034) suggests a long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and the exercise price are typical considerations, often benchmarked against peer companies of similar size and stage of development.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation strategy to attract and retain talent.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant relative to the company's overall capitalization.

Key Dates

Keywords

Vaccinex, Director, Stock Options, Form 4, SEC, VCNX, Beneficial Ownership, Reverse Stock Split, Incentive Plan